Antibody-Drug Conjugates - Bridging Targeted Precision and Potent Cytotoxicity
Antibody-drug conjugates (ADCs) represent a groundbreaking approach in targeted cancer therapy. Alfa Chemistry understands the unique challenges and immense potential of ADCs in modern oncology. Our comprehensive ADC solutions are designed to support your therapeutic vision by delivering precisely engineered components—linkers, payloads, and payload-linker constructs—that optimize targeting, stability, and therapeutic index.
Online Inquiry View Product Categories
- Overview
- History
- Mechanisms
- Products
- Advantages
- Services
- Platforms
- Customer Cases
- Reviews
- FAQs
- Resources
What Are Antibody-Drug Conjugates?
ADCs are formed by chemically linking a monoclonal antibody to a cytotoxic payload via a specialized linker, integrating precision targeting with powerful cell-killing activity to maximize therapeutic outcomes.
ADCs are composed of three essential components:
Antibody
The antibody serves as a highly specific targeting vehicle, recognizing and binding to tumor-associated antigens (such as HER2 or CD30) on the cancer cell surface. Advances in antibody engineering have evolved from early murine antibodies with high immunogenicity to fully humanized IgG1-based antibodies, which offer prolonged half-life and enhanced interactions with Fcγ receptors for improved therapeutic performance.
Linker
The linker plays a critical role in ensuring the stability of the ADC in systemic circulation, preventing premature payload release and minimizing off-target toxicity. Linkers can be cleavable, responding to tumor-specific microenvironment conditions such as low pH, protease activity, or high glutathione levels to enable selective payload release and bystander effects. Alternatively, non-cleavable linkers require lysosomal degradation within target cells to release the payload, offering enhanced stability but typically lacking bystander activity.
Cytotoxic Payload
The payload, or warhead, is a highly potent small-molecule drug with nanomolar to picomolar IC50 values, designed to induce rapid and effective cell death upon internalization. Common payloads include microtubule inhibitors (e.g., MMAE, DM1) and DNA-damaging agents (e.g., calicheamicin), all capable of penetrating cell membranes and eliciting “bystander effects” that extend cytotoxic activity to neighboring tumor cells.
Understanding the History and Development of Antibody-Drug Conjugates
The ADC concept was introduced, initially exploring the use of antibodies to deliver cytotoxic drugs directly to cancer cells to reduce systemic toxicity.
First-generation ADCs are introduced, using a randomized coupling strategy, but efficacy is limited by lack of linker stability and immunogenicity issues.
Second-generation ADCs emerge, using more stable linkers (e.g., peptidase-sensitive linkers) and humanized antibodies, significantly improving efficacy and safety.
Multiple ADC drugs receive FDA approval, signaling the entry of ADCs into the clinical mainstream; multiple linker technologies and novel cytotoxic loads are developed and applied.
Third-generation ADCs and bis-antibody-drug couplings (BsADCs), novel target ADCs, etc., continue to emerge; innovations in antibody engineering and linker and payload technologies drive the development of ADC therapies for precision and multiple indications.
What Are the Mechanisms of Action of Antibody-Drug Conjugates?
ADCs synergize their anti-tumor effects through the following mechanisms:
Target binding and internalization
ADCs bind tumor cell surface antigens, form complexes for endocytosis, and are transported to lysosomes via endosomes.
Load release and direct killing
Lysosomal endo-ligand cleavage, release of load to damage microtubules or DNA and induction of apoptosis.
Indirect immune effects
Antibodies partially activate Fc-mediated effector functions (e.g., ADCC, ADCP, CDC) to recruit immune cells to clear tumors.
Bystander effect
Hydrophobic load penetrates cell membranes and kills antigenically low-expressing or heterogeneous tumor cells, overcoming target heterogeneity.
Explore Our Complete ADC Solutions: Linkers, Payloads, and Payload-Linkers. Start Your Project Today with Alfa Chemistry!
Linkers
View Full Product LineCritical to the stability and functionality of ADCs, linkers are chemical bridges that connect cytotoxic payloads to targeted antibodies. Our broad portfolio includes cleavable and non-cleavable linkers designed to release the payload under specific intracellular conditions, ensuring an optimal therapeutic window and minimizing off-target effects.
Payloads
View Full Product LinePayloads, also known as warheads, are potent cytotoxic agents that induce cell death upon internalization. We offer a broad range of payloads, including microtubule protein inhibitors, DNA-damaging agents and other novel cytotoxic agents to meet the diverse needs of ADC development and preclinical testing.
Payload-linker
View Full Product LineOur innovative payload-linker architecture integrates cytotoxic payloads and linkers into a single entity that can be directly coupled. This streamlined approach not only accelerates ADC development but also improves the consistency and stability of the final coupler.
What Are the Advantages of Antibody-Drug Conjugates?
Precise Targeting
The antibody portion specifically recognizes and binds to tumor-associated antigens, enabling targeting and minimizing toxic damage to normal cells.
Efficient Cytotoxicity
The load is usually a small molecule and highly toxic drug, which can induce apoptosis efficiently in the cell, and the killing efficacy is far more than that of traditional chemotherapeutic drugs.
Bystander Effect
The cleavable linker and part of the payload can diffuse in the tumor microenvironment to the surrounding tumor cells that do not express the target antigen to achieve broad killing.
Reduced Systemic Toxicity
Through antibody-mediated selective delivery, ADC is stable in the blood circulation and activated only within the target tumor cells, significantly reducing systemic side effects.
Diversity of Indications
ADCs are not only applicable to hematological tumors but have also shown significant efficacy in the treatment of a variety of solid tumors, expanding the range of clinical indications for antibody therapy.
How Can Alfa Chemistry Help You with ADCs Development?
Alfa Chemistry merges its deep expertise in chemical synthesis with biocoupling and analytical characterization to deliver full ADC development and optimization solutions. Our team works together with you to create high-quality ADCs according to your specific research needs and therapeutic objectives.
Online Inquiry
Available Services
- Ligand, payload and payload-linker custom synthesis - flexible synthesis capabilities to meet your unique project needs.
- ADC coupling services - site-specific or random coupling to generate homogeneous ADCs with precise DAR.
- Analytical characterization - comprehensive analysis of purity, stability and bioactivity to ensure the highest quality standards are met.
- Scale-up manufacturing - support ADC manufacturing from preclinical to clinical scale and comply with stringent regulatory standards.
- Consulting and project management - Collaborative support at every stage of your ADC program.
Integration with our Drug Discovery Services Platform
For researchers looking to expand their ADC program beyond chemical development, we can seamlessly connect to our integrated [Drug Discovery Services Platform], which includes cutting-edge discovery and optimization services. The platform covers:
By combining ADC development with our platforms, you gain access to a multidisciplinary ecosystem that accelerates the identification of lead compounds, optimizes the selection of drug candidates, and speeds your translation from discovery to clinical application.
What Success Stories Can We Share?
Cas 1492056-71-9
Case 1: Targeted Delivery Using Amino-PEG4-Val-Cit-PAB-MMAE
A research team at a prominent oncology research institute recently procured Amino-PEG4-Val-Cit-PAB-MMAE [Catalog Number YM1492056719] to enhance their targeted cancer therapeutic studies.
The team selected this payload-linker for its proven cathepsin B-cleavable Val-Cit linker system, combined with the PAB self-immolative spacer, ensuring efficient intracellular release of the MMAE payload. The PEG4 spacer also contributes to improved solubility and stability during bioconjugation. In their project, this product is being conjugated to monoclonal antibodies specific to tumor-associated antigens.
Cas 115088-06-7
Case 2: Exploring Linker Stability with SPDB
A group of researchers focused on ADC pharmacokinetics recently purchased the SPDB linker [Catalog Number YM115088067] to study its unique disulfide-based cleavable properties.
Known for its stability in circulation and rapid cleavage in the reducing intracellular environment, SPDB provides valuable insight into balancing in vivo stability with efficient payload release. The research team is incorporating SPDB into various ADC platforms to assess its effect on pharmacokinetics and intracellular payload delivery, aiming to improve therapeutic selectivity and efficacy.
Cas 1222490-34-7
Case 3: Advancing ADC Potency with SGD-1882
A team working on preclinical oncology drug evaluation selected SGD-1882 [Catalog Number YM1222490347] for its potent tubulin-inhibitory activity, essential for ADC payload development. This cytotoxic payload is under investigation in multiple linker systems to compare its in vitro cytotoxicity and evaluate compatibility with targeted antibodies.
The research group is also examining how SGD-1882 influences intracellular trafficking and release kinetics. Initial findings suggest promising results, reinforcing their pursuit of more effective ADC payload strategies.
*All products are intended for scientific use only and are not intended for human therapeutic, diagnostic, or other pharmaceutical use. You can reach out to us for additional product information or technical support.
What Our Clients Say?
Learn how our integrated solutions for ADCs can transform your research. Discuss your specific needs and accelerate your journey to the next generation of targeted therapies.
Call a specialist:
What Our Clients Ask
What types of cytotoxic payloads are commonly used in ADCs?
Common payloads include microtubule inhibitors (e.g., MMAE, DM1), DNA damaging agents (e.g., khakimycin), and other potent small molecules with nanomolar or picomolar activity, depending on tumor type and mechanism of action.
Are these products suitable for clinical use?
No, these products are restricted to scientific use and are not indicated for human or clinical studies.
What is the role of the Val-Cit moiety in Amino-PEG4-Val-Cit-PAB-MMAE?
The Val-Cit motif is a linker that can be cleaved by lysosomal proteases, ensuring that the payload is specifically released inside tumor cells to maximize efficacy.
Can ADC components be customized to meet specific research needs?
Yes, ADC components (e.g., linkers, payloads, and their couplers) can often be customized based on chemical structure, purity, and functional moiety to meet specific experimental or developmental needs.
Do you provide detailed analytical data for these Linkers and Payload-Linkers?
We provide COA and basic analytical data (e.g., HPLC, LC-MS) with the shipment, and more detailed characterization reports are available upon request.
Are these products suitable for in vitro activity testing?
Absolutely, these products are of high purity and consistent quality, making them ideal for in vitro activity screening and ADC potency studies.
What safety precautions should be considered when handling ADC payloads?
Due to the high cytotoxicity of the payloads and couplers, they must be handled with appropriate personal protective equipment (PPE) and in a designated containment facility to minimize the risk of exposure.
If we need services related to ADC process development or bioanalysis, can Alfa Chemistry provide support?
Yes, Alfa Chemistry not only provides high-quality raw materials but can also provide a comprehensive solution for your ADC program in conjunction with our drug discovery services platform.
*If you have further questions, please contact our support team who will help you get the most out of Alfa Chemistry's ADCs solutions.